secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2023-04-20T23:59:59+00:00
Accession:  0001213900-23-031189
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Blue Water Vaccines acquires Veru's ENTADFI for $100M; plans name change to Blue Water Biotech
--------------------------------------------------------------------------------

- Total consideration $100M: $20M upfront (tranches through Sept 2024) plus up to $80M in sales milestones.
- Assumes royalty and milestone obligations up to $22.5M from prior agreement.
- Acquires ~125,000 bottles of ENTADFI, an FDA-approved BPH treatment.
- Company will change name to Blue Water Biotech; CEO Joseph Hernandez leads.
- Frank Jaeger to lead commercialization; previously doubled AndroGel sales to $1.3B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/0001213900-23-031189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/ea177216-8k_bluewater.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-031189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer